Potassium Chloride
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
- Potassium Chloride
- Pharmacist Assessment Report
- Potassium Chloride: From Potassium Deficiency to Renal Tubular Acidosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Potassium Chloride: From Potassium Deficiency to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride is a potassium replacement agent, originally used to treat potassium deficiency and constipation. The TxGNN model predicts it may be useful for renal tubular acidosis, but this is supported by no registered clinical trials and 18 publications, mostly case reports and reviews, so the evidence is weak. The benefit is most plausibly limited to correcting the low potassium that accompanies the condition, not treating the acidosis itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease; constipation disorder |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L4 (no clinical trials; case reports, reviews and mechanistic reasoning only) |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium chloride is a potassium replacement agent. Its efficacy in potassium deficiency is well established, and mechanistically it may be applicable to the low potassium seen in renal tubular acidosis.
Distal (type 1) renal tubular acidosis commonly causes hypokalaemia through impaired distal hydrogen-ion secretion and renal potassium wasting. Potassium repletion is therefore a recognised supportive measure. Several case reports in the literature describe patients with severe hypokalaemia from this condition, often linked to Sjögren’s syndrome, who were treated with potassium chloride.
The link is corrective, not disease-modifying. It addresses the associated electrolyte disturbance, not the acidosis itself. Alkali therapy (bicarbonate or citrate salts) is the primary treatment in practice. Potassium citrate is often preferred over potassium chloride because it also corrects the acidosis. Chloride as the accompanying anion may even worsen acidosis in some settings.
The very high TxGNN score most likely reflects overlap between the existing “potassium deficiency” indication and the hypokalaemia associated with this condition. It should not be read as evidence of a new therapeutic mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Of the 18 publications retrieved, the most relevant are listed below. Case reports and reviews dominate; no randomised trials were found.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6277192 | 1982 | Review | Am J Med | Review of distal nephron function and its disorders |
| 786013 | 1976 | Review | Am J Med Sci | Causes, consequences and correction of hypokalaemia |
| 38445406 | 2023 | Cohort/Genetic study | Tunis Med | Genotype-phenotype correlation of distal RTA in Tunisia; hypokalaemia and nephrocalcinosis are typical features |
| 10213645 | 1999 | Cohort | Am J Kidney Dis | Metabolic acidosis in advanced renal failure, comparing diabetic and non-diabetic patients |
| 40288831 | 2025 | Case report with review | Nefrologia | Primary RTA during pregnancy and perinatal prognosis |
| 34748193 | 2022 | Case report | J Nephrol | Distal RTA with hypokalaemic periodic paralysis during pregnancy |
| 37727491 | 2023 | Case report | World J Clin Cases | Incomplete distal RTA uncovered during pregnancy |
| 34595212 | 2021 | Case report | Case Rep Nephrol Dial | Type I RTA with severe hypokalaemia (K 1.6 mEq/L) in Sjögren’s/SLE, treated with potassium chloride infusion |
| 40654398 | 2024 | Case report | JNMA | Sjögren’s syndrome presenting as severe hypokalaemia, treated with intravenous potassium chloride |
| 39091614 | 2024 | Case report | Clin Case Rep | Hypokalaemic quadriplegia in Sjögren’s syndrome; early detection of hypokalaemia is stressed |
Canada Market Information
Health Canada lists 20 valid single-ingredient authorisations, all injectable or infusion products. The data compiled for this report do not include dosage forms or approved indication text. The first five are shown below.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02529793 | Potassium Chloride for Hemodialysis 7.55 | Not specified | Not specified |
| 02485699 | Potassium Chloride for Injection Concentrate USP | Not specified | Not specified |
| 00402206 | Potassium Chloride for Injection Concentrate | Not specified | Not specified |
| 00037869 | Potassium Chloride for Injection Concentrate USP | Not specified | Not specified |
| 02241676 | Potassium Chloride Injection | Not specified | Not specified |
The other 15 products are potassium chloride premixed with dextrose and/or sodium chloride solutions, plus one product named K+ 45.
Safety Considerations
Contraindications flagged in the knowledge graph (not label text): The TxGNN knowledge graph links potassium chloride to 30 conditions as contraindications. The main groups are:
- Kidney and urinary: kidney disease, anuria, nephrocalcinosis
- Cardiovascular: congestive heart failure, heart disease, coronary artery disease, hypertension
- Gastrointestinal: gastric ulcer, peptic ulcer disease, pancreatitis
- Other: liver disease, hypercalcaemia, sickle cell anaemia, hereditary haemochromatosis, Wilson disease
Kidney disease and nephrocalcinosis are especially relevant here, because nephrocalcinosis is a common complication of distal RTA.
Drug interactions: A total of 100 interactions were found. The main ones include:
- Major: amiloride, benazepril, olmesartan, valsartan, azilsartan medoxomil and aliskiren (moderate). Combining these with potassium chloride risks hyperkalaemia.
- Major: anticholinergic and antihistamine agents, including atropine, hyoscyamine, homatropine, glycopyrronium, benzatropine, biperiden, amitriptyline, chlorpheniramine, brompheniramine, acrivastine and phenyltoloxamine.
- Moderate: ketorolac and ibuprofen.
- Minor: cyanocobalamin.
Package insert warnings and contraindications from Health Canada were not available, so please refer to the package insert for label-based safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials support this prediction, and the literature consists mainly of case reports in which potassium chloride treats associated hypokalaemia. The high TxGNN score probably reflects overlap with the existing potassium deficiency indication, not a new mechanism. Alkali therapy is the standard treatment, and chloride may worsen acidosis.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A clear comparison of potassium chloride against potassium citrate or alkali therapy in distal RTA
- Reframing the question as supportive hypokalaemia management in RTA, not as treatment of the disease itself
- Safety review for patients with kidney impairment, nephrocalcinosis, and concurrent potassium-raising drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.